Related by context. All words. (Click for frequent words.) 61 metastatic malignant 61 allogeneic hematopoietic stem cell 60 interferon lozenges 60 colorectal cancer liver metastases 60 autologous transplant 60 PEG IFN 59 epoetin alpha 59 CLL SLL 59 Allogeneic 59 gefitinib Iressa 58 gastrointestinal stromal tumors GIST 58 neoadjuvant chemotherapy 58 prostate carcinoma 58 ASCT 58 stem cell engraftment 58 transplant ASCT 58 bevacizumab Avastin ® 57 Myelodysplastic Syndrome MDS 57 adjuvant cisplatin 57 Doxil ® 57 cetuximab Erbitux ® 57 NOD SCID mice 57 generation purine nucleoside 57 pancreatic adenocarcinoma 57 radioimmunotherapy RIT 57 leukemia AML 57 dose melphalan 57 targeted antifolate 57 Cloretazine 56 Pegylated Interferon 56 etoposide 56 HSCT 56 receiving highly emetogenic 56 Selective Internal 56 Flu Cy 56 Sutent sunitinib 56 liposomal doxorubicin 56 syngeneic 56 ribavirin RBV 56 TACE 56 allogeneic transplant 56 myeloid metaplasia 56 sorafenib Nexavar 56 immunomodulatory therapy 56 sunitinib Sutent 56 bevacizumab Avastin 55 randomized multicenter trial 55 TKI therapy 55 mRCC 55 refractory acute myeloid 55 metastatic renal cell carcinoma 55 administered intraperitoneally 55 Decitabine 55 fludarabine cyclophosphamide 55 BrachySil TM 55 Gleevec resistant 55 xenograft 55 underwent liver transplantation 55 debulking surgery 55 uricase 55 pT2 55 biliary tract cancer 55 malignant ascites 55 Azacitidine 55 autologous transplants 55 busulfan 55 hA# 55 intratumoral injection 55 cetuximab Erbitux R 55 ibritumomab tiuxetan 55 imatinib mesylate Gleevec 55 thalidomide Thalomid 55 Degarelix 55 imatinib Gleevec 55 allogeneic transplants 55 Zybrestat 55 adjuvant radiotherapy 55 concurrent chemoradiation 55 radioiodine therapy 55 CRp 55 DCVax 55 null responder 55 recurrent glioblastoma multiforme 55 Phase Ib IIa clinical 55 novel vascular disrupting 55 autologous SCT 55 relapsed ALL 55 Belldegrun 55 SIR Spheres 55 Tyrosine Kinase Inhibitors 55 Interferon alfa 55 Multiple Myeloma MM 55 daily subcutaneous injections 55 Pharmacokinetics PK 55 depsipeptide 54 caspofungin 54 dose dexamethasone 54 cilengitide 54 bronchoalveolar lavage fluid 54 prostate cancer mCRPC 54 pediatric acute lymphoblastic 54 5-fluorouracil/leucovorin 54 BALF 54 fallopian tube carcinoma 54 Annamycin 54 ara C 54 OHR/AVR# 54 colon carcinoma 54 murine model 54 irinotecan chemotherapy 54 multikinase inhibitor 54 MGd 54 topically administered 54 external beam radiotherapy 54 haematological cancers 54 unresectable inoperable 54 autologous transplantation 54 bFGF 54 dasatinib Sprycel 54 Copegus ribavirin 54 metastatic malignant melanoma 54 neoadjuvant setting 54 pancreatic islet cell 54 ClearPath HDR 54 renal tumors 54 multiple myeloma MM 54 renal transplantation 54 viral kinetics 54 neo adjuvant chemotherapy 54 bortezomib Velcade 54 Evaluable 54 cytotoxic therapy 54 HIPEC 54 multicenter randomized controlled 54 stem cell transplantation 54 ErbB2 positive 54 recurrent GBM 54 hypomethylating agent 54 antibody MAb 54 predictive biomarker 54 HERCEPTIN 54 VNP#M 54 pharmacodynamic PD 54 LHRH receptor positive 54 dasatinib Sprycel ® 54 Leucovorin 54 neoadjuvant treatment 54 Lenalidomide 54 Campath alemtuzumab 54 pretransplant 54 xenograft model 54 bladder carcinoma 54 bacillus Calmette Guerin 54 Fludarabine 54 NovoTTF #A 54 Intra arterial 54 Surgical resection 54 adjuvant tamoxifen 54 basiliximab 54 myocardial revascularization 54 gemcitabine cisplatin 54 #F FDG 54 OvaRex MAb 54 autologous stem cell 53 pegylated interferon alfa 53 intravesical therapy 53 autologous hematopoietic stem cell 53 mutated K ras 53 Mutation Analysis 53 Radiofrequency Ablation RFA 53 ritonavir boosted 53 nonmyeloablative 53 alefacept 53 Trastuzumab 53 LVRS 53 FOLFOX4 53 intravesical instillation 53 cell lymphoma CTCL 53 Imatinib 53 verteporfin 53 Enzyme Replacement Therapy 53 Kantarjian 53 Velcade bortezomib 53 chemotherapy docetaxel 53 azacytidine 53 Platinol ® 53 intravesical chemotherapy 53 Panzem R NCD 53 molecular remissions 53 myeloablative 53 lymphoid malignancies 53 gemcitabine Gemzar ® 53 PROCRIT R 53 Percutaneous Tibial Nerve Stimulation 53 cisplatin chemotherapy 53 chemo resistant 53 alpha 2a 53 refractory prostate cancer 53 bispecific antibody 53 operable breast cancer 53 Interferon Alfa 53 Pegylated Liposomal Doxorubicin 53 immunosuppressant drug 53 cytoreduction 53 induce remission 53 vivo preclinical 53 Peginterferon 53 satraplatin Phase 53 antithymocyte globulin 53 total abdominal hysterectomy 53 ixabepilone 53 pegylated liposomal doxorubicin 53 orthotopic 53 renal artery stenting 53 cells PBMC 53 rt PA 53 abacavir Ziagen 53 farletuzumab 53 hMG 53 5 Fluorouracil 53 Neoadjuvant 53 stage IIIB 53 anagrelide 53 intra arterial 53 melphalan prednisone 53 pertuzumab 53 thalidomide dexamethasone 53 posttransplant 53 laparoscopic radical nephrectomy 53 PEG Interferon 53 p# MAP kinase inhibitor 53 TPV r 53 SCIg 53 chronic hemodialysis 53 paricalcitol 53 denileukin diftitox 53 chemoresistant 53 Irinotecan 53 trastuzumab Herceptin 53 Aflibercept 53 radiofrequency ablation RFA 53 adult mesenchymal stem 53 Mesenchymal Stem Cells 53 chemoradiotherapy 53 prostate cancer CRPC 53 Btk Inhibitor 53 Myelodysplastic Syndrome 53 histone deacetylase inhibitor 53 immunoconjugate 53 Erlotinib 53 decitabine 53 colorectal liver metastases 53 Kinoid 53 Mantle Cell Lymphoma 53 rituximab Rituxan 53 KSP inhibitors 53 hybridoma cell 53 humanized antibody 53 cytoreductive nephrectomy 52 relapsing multiple sclerosis 52 PTK# 52 EGFR TKI 52 pharmacokinetic PK study 52 solid organ transplantation 52 Pertuzumab 52 2DG 52 polycythemia vera essential thrombocythemia 52 Solid Tumors 52 surgically resectable 52 peritoneal carcinomatosis 52 MIBG 52 gastroesophageal cancer 52 QLT# 52 Retreatment 52 peritoneal dialysis PD 52 heavily pretreated patients 52 localized renal 52 peginterferon alfa 2a #KD 52 RAS mutations 52 Lucanix 52 Fully Covered Stent 52 Omacetaxine 52 intravesical 52 carboplatin paclitaxel 52 reteplase 52 Hematopoietic stem cell 52 Alequel 52 glatiramer acetate GA 52 OvaRex 52 HLA DR4 52 metastatic gastric 52 castrate resistant 52 neoadjuvant 52 CRRT 52 Tyrosine Kinase Inhibitor 52 Mammosite 52 administered subcutaneously 52 transplantation HSCT 52 oblimersen 52 refractory chronic myeloid 52 Phase Ib Clinical Trial 52 Sipuleucel T 52 recurrent metastatic 52 peginterferon alpha 52 imatinib therapy 52 miglustat 52 Phase IIb clinical trials 52 paclitaxel Taxol 52 omacetaxine mepesuccinate 52 trastuzumab Herceptin ® 52 relapsed refractory 52 mononuclear 52 PARP inhibitor 52 FOLFOX6 52 Progenitor Cells 52 radiotherapeutic 52 Rituximab 52 Phase #b/#a trial 52 Gemzar gemcitabine 52 Gliadel Wafer 52 demethylating agent 52 refractory colorectal cancer 52 refractory CLL 52 ribavirin Copegus ® 52 hemodialysis patients 52 interstitial brachytherapy 52 diagnostic biomarker 52 mitomycin 52 microsphere therapy 52 sipuleucel T 52 fluorouracil 52 fosbretabulin 52 therapy 52 IN VITRO 52 Hodgkin lymphoma NHL 52 allogeneic hematopoietic cell 52 galiximab 52 TOP2A 52 AQ4N 52 cranial irradiation 52 Kogenate R 52 Pemetrexed 52 heavily pretreated 52 metastatic uveal melanoma 52 keratoplasty 52 refractory ovarian cancer 52 Vidaza azacitidine 52 subcutaneous immunoglobulin 52 transplant HSCT 52 Sorafenib 52 biologic therapy 52 imatinib Gleevec ® 52 MAb 52 HALO# [002] 52 Interferon beta 52 huN# DM1 52 NSCLC tumors 52 nephrectomy 52 Cytoxan ® 52 paclitaxel Taxol R 52 relapsed MM 52 interferon ribavirin 52 PEGPH# 52 Monoclonal antibody 52 5 fluorouracil leucovorin 52 Endothelial 52 protease inhibitor PI 52 GRNVAC1 52 mitoxantrone chemotherapy 52 erlotinib Tarceva ® 52 MDS AML 52 undergoing hematopoietic stem 52 Janus Kinase 52 SBRT 52 receptor tyrosine kinase inhibitor 52 PKC# 52 ISF# 52 temozolomide TMZ 52 haematologic malignancies 52 chemoradiation therapy 52 care regimens CCR 52 relapsed AML 52 urothelial carcinoma 52 GHRH 52 Cyclosporin 52 Factor VIIa 52 biochemical relapse 52 fallopian tube cancers 52 MyVax ® 52 colony stimulating factors 52 G CSF 52 Angiotensin Converting Enzyme 52 transplantation HCT 52 Waldenstrom macroglobulinemia 52 antiproliferative effects 52 IFN alpha 2a 52 dimeglumine 52 PD2i ® 52 Accelerated Partial Breast Irradiation 52 PSMA ADC 52 Adult Stem Cell Therapy 52 fistulizing Crohn disease 52 autologous bone marrow 52 atypical Hemolytic Uremic Syndrome 52 neurologic progression 52 hibernating myocardium 52 interferon therapy 51 Ontak 51 tinzaparin 51 Tumor Microenvironment 51 olaparib 51 Cetuximab Erbitux 51 GRASPA ® 51 Cell Lymphoma 51 Solid Tumors criteria 51 ORAL HYCAMTIN 51 Dacogen decitabine 51 Cellular Immunotherapy 51 tyrosine kinase inhibitor 51 Autologous 51 vidofludimus 51 hepatic encephalopathy HE 51 GRNCM1 51 antiangiogenic agent 51 Initiate Clinical Trial 51 carmustine 51 transarterial chemoembolization 51 gastrointestinal stromal tumor GIST 51 preclinical efficacy 51 noninvasive imaging 51 pT3 51 chemotherapeutic regimen 51 Morpholino 51 M Vax 51 PPAR gamma agonist 51 humanised monoclonal antibody 51 polycythemia vera PV 51 dose escalation clinical 51 eribulin mesylate 51 laparoscopic partial nephrectomy 51 BrachySil ™ 51 induced cytotoxicity 51 Kamada AAT 51 prostate adenocarcinoma 51 chlorambucil 51 MAGE A3 51 JAK2 V#F 51 T1a 51 ovarian carcinoma 51 Eligen R B# 51 metastatic castration resistant 51 therapy IMRT 51 Metastatic Melanoma 51 estramustine 51 peginterferon alpha 2a 51 C#BL 6 mice 51 CsA 51 Vascugel ® 51 cidofovir 51 Modrenal 51 preoperative chemotherapy 51 Gefitinib 51 imatinib resistant 51 renal transplant 51 TransMID 51 Allograft 51 radiation therapy SBRT 51 bronchoalveolar lavage 51 prognostic biomarker 51 antithrombotic therapy 51 belatacept 51 Antiangiogenic 51 ZACTIMA 51 adalimumab Humira 51 Avastin Tarceva 51 intradermal injections 51 renoprotective 51 cynomolgus monkeys 51 oral clodronate 51 Antigen CEA 51 PSA nadir 51 immunosuppression therapy 51 gemcitabine Gemzar 51 stereotactic radiotherapy 51 Rituxan rituximab 51 DAPT 51 adefovir dipivoxil 51 myeloproliferative disease 51 Radiation Therapy SIRT 51 mTOR inhibitors 51 pig islets 51 lapatinib Tykerb 51 Exemestane 51 OPCAB 51 Cetuximab 51 atypical hemolytic uremic syndrome 51 tositumomab 51 undetectable HBV DNA 51 refractory chronic lymphocytic 51 TLK# 51 PKCi 51 temozolomide 51 liposomal formulation 51 LCP Tacro 51 fluvastatin 51 elevated transaminases 51 immunotherapeutic vaccine 51 E1 INT TM 51 standard chemotherapy regimen 51 anti CD3 antibody 51 Melphalan 51 Trofex 51 Radioimmunotherapy 51 prostate cancer HRPC 51 parenteral antibiotics 51 novel immunotherapeutic 51 Photodynamic 51 pamidronate 51 histologically proven 51 Cyclophosphamide 51 systemic RNAi therapeutic 51 tenecteplase 51 antiangiogenic therapy 51 Virologic 51 factor G CSF 51 rFSH 51 INFUSE ® 51 radiotherapy RT 51 Oxaliplatin 51 insulin glulisine 51 rBChE 51 NSABP B 51 mCRC patients 51 gene expression profiling 51 Chronic Myelogenous Leukemia 51 ascending dose 51 thrombocythemia 51 CDK inhibitor 51 pancreatic carcinoma 51 stem cell mobilizer 51 anti angiogenic agents 51 radiotherapy SBRT 51 GW# [003] 51 Belatacept 51 Septin9 51 tiuxetan 51 biotherapy 51 CD# + [001] 51 Breast Brachytherapy 51 liposomal amphotericin B 51 HDAC Inhibitor 51 phase IIIb 51 stereotactic radiosurgery SRS 51 hESC derived cardiomyocytes 51 VitiGam TM 51 recurrent NSCLC 51 #F ML 51 Elitek 51 bevacizumab Avastin R 51 corticosteroid dexamethasone 51 metastatic RCC 51 Sirolimus eluting 51 Bevacizumab Avastin 51 hematological relapse 51 IFN Beta 51 ISTODAX ® 51 HuMax 51 Kahalalide F 51 F FDG PET 51 immunotherapy 51 dose cyclophosphamide 51 relapsed ovarian cancer 51 Amrubicin 51 mg kg BID 51 pegylated interferon alpha 51 bendamustine 51 fulvestrant 51 Bendamustine 51 randomized multicenter Phase III 51 HuMax CD4 51 reductase inhibitors 51 trabectedin 51 targeted radiotherapeutic 51 achieved sustained virological 51 ChronVac C R 51 pegfilgrastim 51 RECIST Response Evaluation Criteria 51 Inosine 51 follicular NHL 51 orthotopic liver transplantation 51 HER2 antibody 51 monoclonal antibody conjugated 51 urothelial bladder cancer 51 murine models 51 Inhaled AAT 51 Cytochrome P# 51 5FU 51 IDO inhibitor 51 pancreatic neuroendocrine tumors 51 Derived Factor 51 eosinophilic asthma 51 CINTREDEKIN BESUDOTOX 51 pancreatic transplantation 51 Photodynamic therapy 51 genitourinary cancers 51 monoclonal anti 51 gastrointestinal stromal tumors GISTs 51 peptide conjugated 51 cardiac perfusion 51 sunitinib 51 ELAD 50 KRAS wild 50 Cloretazine ® 50 underwent resection 50 Sorafenib Nexavar 50 eluting stent 50 Neuvenge 50 skip exon 50 haematopoietic stem cell 50 CRLX# 50 immunomodulatory therapies 50 metastatic lung cancer 50 rFVIII 50 Bortezomib 50 abiraterone acetate 50 rFVIIa 50 allogeneic SCT 50 rHuEPO 50 pancreatic ductal 50 irreversible inhibitor 50 Phase III randomized controlled 50 patientswith 50 VitiGam 50 hematopoietic progenitor cells 50 ABVD 50 unresectable stage 50 anthracycline containing 50 AMEVIVE 50 FLT3 ITD 50 liver resection 50 HCV Genotype 50 Cystoscopy 50 HBV vaccine 50 Intravesical 50 Neo Bladder Augment 50 sacrocolpopexy 50 Idiopathic Pulmonary Fibrosis 50 Allovectin 7 50 dermal collagen 50 Onrigin 50 DEB# 50 interferon alfa 2a 50 trastuzumab 50 intracavitary 50 alfa 2a 50 Gleevec imatinib 50 volociximab 50 rhBMP 2 50 mCRPC 50 Gemcitabine 50 bone marrow progenitor cells 50 thyroglobulin 50 coenzyme Q 50 sunitinib malate 50 Clolar ® 50 temozolomide Temodar 50 Globulin 50 azacitidine 50 Endometrial 50 breast carcinoma 50 IV NSCLC 50 Stereotactic Body Radiation Therapy 50 somatostatin analogue 50 IFN α 50 ACE Inhibitor 50 certolizumab 50 ESBA# 50 cetuximab Erbitux 50 colorectal carcinoma 50 euthyroid 50 valve implantation 50 TheraGuide 50 axitinib 50 cancer mCRC 50 Proteasome 50 cellular immunotherapy 50 imatinib 50 doxorubicin docetaxel 50 Tacrolimus 50 Assay Kits 50 hepatectomy 50 dexamethasone Decadron 50 Eli Lilly Gemzar 50 noninferior 50 peg interferon 50 multicenter clinical 50 gemtuzumab ozogamicin 50 histological subtype 50 erythropoietic 50 lenalidomide Revlimid 50 Acute Myeloid Leukemia 50 RENAL 50 Allogeneic Stem 50 cutaneous melanoma 50 dexpramipexole 50 NPC 1C 50 vitro cytotoxicity 50 CD3 monoclonal antibody 50 liver metastasis 50 ibandronate 50 Noxafil 50 balloon valvuloplasty 50 proteasome inhibitor bortezomib 50 ErbB3 receptor 50 erlotinib Tarceva 50 pan HDAC inhibitor 50 induced phosphorylation 50 Patient Registry 50 tumorigenicity 50 dose cohort 50 receptor blocker 50 Kinase Inhibitor 50 Bruton tyrosine kinase Btk 50 Immunomodulatory 50 radiolabeled antibodies 50 urography 50 demonstrated antitumor activity 50 SEPET TM 50 Talotrexin 50 tyrosine kinase inhibitors TKIs 50 Neupogen ® 50 sedative pentobarbital sodium 50 olmesartan 50 metastatic neuroendocrine tumors 50 multicenter clinical trials 50 Remune 50 Peripheral Blood 50 PegIFN 50 etanercept Enbrel 50 Antiviral Therapy 50 Liposomal 50 Capesaris 50 cisplatin resistant 50 non nucleoside 50 allogeneic stem cell 50 peginterferon 50 hematopoietic cell 50 PROLARIS 50 Cellcept 50 chemosensitivity 50 colony stimulating factor 50 thrombocytopenic 50 assessing T DM1 50 CellSearch ™ 50 p# inhibitor 50 Naive Patients 50 HER2 positive metastatic breast 50 EOquin TM 50 Cimzia TM 50 ASSERT trial 50 beta interferons 50 Solid Tumours 50 BCG refractory 50 rituximab 50 undergoing peritoneal dialysis 50 Myocardial 50 RRM1 50 Electronic Brachytherapy 50 IL# PE#QQR 50 pDCs 50 eniluracil 50 NMIBC 50 Phase IIb IIIa 50 essential thrombocythemia ET 50 tumors GIST 50 cutaneous T 50 Phase Ib clinical 50 PathFinderTG 50 adjuvant therapy 50 taxane refractory 50 Potent Inhibitor 50 Torisel 50 nab paclitaxel 50 intratympanic 50 mCi 50 HLA A2 50 BRCA deficient 50 papillary renal cell carcinoma 50 Mesenchymal 50 aPTT 50 palifermin 50 mutated KRAS 50 Follicular Lymphoma 50 pacemaker implantation 50 Fluconazole 50 Patients Treated With 50 multicenter phase 50 radiolabelled 50 FOLFIRI alone 50 G CSFs 50 refractory metastatic 50 extracorporeal membrane oxygenation 50 ß blockers 50 resected tumors 50 peripheral blood mononuclear 50 antimetabolite 50 nonmetastatic 50 vivo validation 50 LDR brachytherapy 50 Shc 50 resectable 50 immunotherapy treatments 50 HER2 amplification 50 intravenous immunoglobulin IVIg 50 mTOR inhibitor 50 Hematopoietic 50 alkylating agents 50 antiangiogenic drugs 50 previously untreated follicular 50 leukemia ALL 50 relapsed multiple myeloma 50 inhibitor RG# 50 smoldering myeloma 50 Evoltra 50 Abstract Number 50 Revlimid lenalidomide 50 pegylated interferon alfa 2b 50 II Clinical Trial 50 subcutaneously administered 50 ALK inhibitors 50 murine monoclonal antibody 50 flow cytometric 50 alemtuzumab Campath 50 Adefovir 50 KRAS mutations occur 50 Glivec imatinib 50 CVac 50 temsirolimus Torisel ® 50 paclitaxel carboplatin 50 metastatic colorectal 50 Adjunctive 50 Ceflatonin 50 hyperoxaluria 50 radioimmunotherapy 50 Estrogen Receptor 50 KRN# 50 EBUS FNA 50 flavopiridol 50 oral tyrosine kinase 50 TURBT 50 node dissection 50 thyroid hormone receptor 50 radiation dosimetry 50 IIa trials 50 Resten MP 50 humanized monoclonal 50 palliative radiotherapy 50 randomized blinded 50 Immunohistochemical analysis 50 BCR ABL inhibitor 50 intraperitoneally 50 paclitaxel poliglumex 50 urine dipstick 50 gastrointestinal stromal tumors 50 gemcitabine carboplatin 50 platelet inhibitor 50 #Gy 50 cystectomy 50 selective modulator 50 Immunotherapeutic 50 inhaled treprostinil 50 clinically meaningful efficacy 50 intratumoral 50 Aurora Kinase 50 Zarnestra 50 prior chemotherapy regimens 50 idiopathic myelofibrosis 50 Mitomycin C 50 docetaxel Taxotere 50 bleomycin 50 microwave hyperthermia 50 transcranial Doppler ultrasound 50 locoregional disease 50 5q deletion 50 Inhalation Solution 50 subcutaneous SC 50 fibrillation AF 50 leukemic stem cells 50 Traficet EN 50 radical cystectomy 50 Phase 2a trial 50 unresectable tumors 50 B Cell Lymphoma 50 EGFR TKIs 50 Cutaneous T 50 Bosentan 50 micafungin 50 cells hESCs 50 dose cytarabine 50 multicentre randomized 50 prostate cancer PCa 50 AdnaTest 50 LEUKINE 50 Her2/neu 50 dacarbazine chemotherapy 50 resected pancreatic cancer 50 HBeAg + 50 liposome formulation 50 Kinase Inhibitors 50 Gleevec imatinib mesylate 50 Feasibility Trial 50 liver metastases 50 Thrombin 50 Critical Limb Ischemia CLI 50 LHRH 49 Cystectomy 49 APTIVUS 49 intralesional 49 subcutaneously injected 49 Partial Nephrectomy 49 Polymerase Inhibitor 49 adriamycin 49 GAMMAGARD 49 Electronic Brachytherapy eBx 49 p# biomarker 49 4mg/kg 49 EGFR receptor 49 stage IIIb 49 prostate cancer AIPC 49 Bone marrow transplantation 49 Oncologic 49 radical nephrectomy 49 undergoing liver transplantation 49 Mycophenolate Mofetil 49 OrCel 49 imatinib resistance 49 non squamous 49 PET imaging 49 leukapheresis 49 NAVISTAR R 49 Chronic Myeloid Leukemia CML 49 DCVax ® Brain 49 PDGFRA 49 Helicobacter pylori eradication 49 oral COTI 49 urothelial cancer 49 deletion 5q 49 Lucentis ranibizumab Genentech 49 MR Angiography 49 PI3 kinase inhibitor 49 ERCC1 49 vinca alkaloid 49 Intravitreal 49 IRESSA 49 MyVax 49 mapatumumab 49 Quinamed 49 mitomycin C 49 Diffuse Large B 49 microsatellite instability 49 Patency 49 biventricular 49 induced neuropathy 49 stage IIIb IV 49 IIa trial 49 GvHD 49 Subcutaneous 49 Sprycel dasatinib 49 underwent radical cystectomy 49 cediranib 49 mycophenolate mofetil 49 Phase Ib study 49 lenalidomide Revlimid R 49 baseline LDH 49 adenoviral 49 CHOP chemotherapy 49 Biphasic 49 Cx# [002] 49 Neulasta ® 49 acute myeloid 49 vandetanib 49 tipranavir r 49 thyroid carcinoma 49 pentostatin 49 transarterial 49 FVIIa 49 vasopressor 49 pediatric pontine glioma 49 leukocyte count 49 uterine fibroid 49 hypercholesterolemic 49 lymphomas leukemias 49 SYN# 49 PARP inhibition 49 transthyretin TTR mediated amyloidosis 49 investigational immunotherapy 49 Dendritic Cell 49 Temozolomide 49 Triapine